Key Development An older patient moving through five or six specialist clinics and receiving five or six separate prescriptions is... Read more
Category: Uncategorized
APOE4 AND BRAIN-VESSEL DAMAGE: ALZHEIMER’S MAY NEED TO BE TREATED BEYOND NEURONS AND AMYLOID
Key Development New research challenges the assumption that vascular damage in Alzheimer’s disease is primarily a downstream consequence. In APOE4... Read more
EV71 VACCINE ARRIVES IN VIETNAM: ITS BIGGEST VALUE IS NOT ELIMINATING HFMD, BUT REDUCING ITS MOST DANGEROUS COMPONENT
Key Development Vietnam now has its first specific preventive tool against EV71 — but it is not a vaccine against... Read more
FDA APPROVES JUVMO: ABBVIE IS BUILDING A PARKINSON’S FRANCHISE FROM EARLY THERAPY TO ADVANCED DISEASE
Key Development Juvmo does not replace levodopa. But it gives AbbVie a new dopamine mechanism that can move the company... Read more
WEGOVY PILL VS FOUNDAYO: THE ORAL GLP-1 RACE IS BEING DECIDED BY ACCESS, NOT EFFICACY ALONE
Key Development Oral GLP-1 therapy has moved beyond being a more convenient alternative to injections. It is becoming a commercially... Read more
HANOI ONCOLOGY HOSPITAL DELEGATES TEMPORARY LEADERSHIP: THE REAL TEST IS WHETHER THE INSTITUTION CAN OPERATE WITHOUT DEPENDING ON ONE INDIVIDUAL
Key Development On September 23, 2026, Hanoi Oncology Hospital Director Bui Vinh Quang formally delegated hospital management responsibilities to Deputy... Read more
HOAN MY EARNS VND2.35 TRILLION IN FOUR YEARS: VIETNAM’S PRIVATE HOSPITAL MARKET IS ENTERING THE SCALE-ECONOMICS PHASE
Key Development Nearly VND2.35 trillion in cumulative net profit over four years is notable. More strategically important, however, is that... Read more
FIVE BIDIPHAR PRODUCTS WIN VIETNAM NATIONAL BRAND STATUS: LOCAL PHARMA IS MOVING FROM “CAN MAKE” TO “CAN MAKE SPECIALTY DRUGS”
Key Development Three of Bidiphar’s five products recognized under Vietnam National Brand 2026 are oncology drugs. That matters more strategically... Read more
ROCHE AND IONIS ADVANCE RNA THERAPEUTICS INTO THE HIGH-STAKES IgA NEPHROPATHY ARENA
Key Development Roche and Ionis Pharmaceuticals have reported successful topline Phase 3 interim results for their investigational antisense oligonucleotide (ASO),... Read more








